LOCATION
Y- age
Carnosine
LifeWave Y-Age Carnosine patches play a crucial role in muscle repair and recovery. When muscles undergo stress or exertion, microscopic damage occurs at the cellular level, triggering the need for repair. Carnosine, a naturally occurring dipeptide found abundantly in muscle tissue, plays a vital role in this process by buffering against the accumulation of lactic acid and oxidative stress, both of which contribute to muscle fatigue and damage. By stimulating the production of carnosine within the body, LifeWave Y-Age Carnosine patches help accelerate the muscle repair process, allowing for faster recovery and enhanced performance. Whether you’re an athlete striving to optimize your training regimen or simply seeking to support your active lifestyle, these patches offer a holistic solution for promoting muscle repair and overall well-being. Experience the transformative effects of enhanced muscle recovery and unlock your body’s full potential with LifeWave Y-Age Carnosine patches. Ready to take the first step towards better muscle health? Click the link in our bio to learn more and discover the power of LifeWave today!
"Y-Age Carnosine Patches• Clinically shown to increase stamina by up to 125%*• Improves strength and flexibility• Improves overall health• Improves bioelectrical properties of organs• Patented, proprietary form of phototherapy• No drugs, chemicals or stimulants"
Abstract type 2 diabetic
We previously demonstrated that polymorphisms in the carnosinase-1 gene (CNDP1) determine the risk of nephropathy in type 2 diabetic patients. Carnosine, the substrate of the enzyme encoded by this gene, is considered renoprotective and could possibly be used to treat diabetic nephropathy (DN). In this study, we examined the effect of carnosine treatment in vivo in BTBR (Black and Tan, BRachyuric) ob/ob mice, a type 2 diabetes model which develops a phenotype that closely resembles advanced human DN. Treatment of BTBR ob/ob mice with 4 mM carnosine for 18 weeks reduced plasma glucose and HbA1c, concomitant with elevated insulin and C-peptide levels. Also, albuminuria and kidney weights were reduced in carnosine-treated mice, which showed less glomerular hypertrophy due to a decrease in the surface area of Bowman’s capsule and space. Carnosine treatment restored the glomerular ultrastructure without affecting podocyte number, resulted in a modified molecular composition of the expanded mesangial matrix and led to the formation of carnosine-acrolein adducts. Our results demonstrate that treatment with carnosine improves glucose metabolism, albuminuria and pathology in BTBR ob/ob mice. Hence, carnosine could be a novel therapeutic strategy to treat patients with DN and/or be used to prevent DN in patients with diabetes.